Multi-institutional team applies TIMING to explain differences in tumor rejection kinetics featuring CellChorus®
Differences in dynamics explain the distinct cytolytic behavior of CAR T cell therapy and can guide engineering of more adaptive and effective cellular products
HOUSTON, Texas — January 28, 2025. CellChorus®, the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced a publication by an interdisciplinary multi-institutional team from three top research universities that extensively applied the CellChorus® TIMING™ platform (Time-lapse Imaging Microscopy In Nanowell Grids) to test how different types of CAR T cells eradicate tumors. The TIMING platform was used to map the dynamics of CAR T cell interactions with tumor cells as a function of the CAR being used in two different clinical products. The results of the study will help guide the design of CAR T cell therapies for more effective, personalized treatment.
